Response to antifibrotic therapy and decrease of circulating BAG3 protein levels in systemic sclerosis patients with reduced forced vital capacity

Biomed Pharmacother. 2024 May:174:116578. doi: 10.1016/j.biopha.2024.116578. Epub 2024 Apr 11.

¹ Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of Salerno, Baronissi, Italy; FIBROSYS s.r.l., Academic spin-off, University of Salerno, Baronissi, Italy.
² Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of Salerno, Baronissi, Italy.
³ Scleroderma Clinic, UOC Clinica Reumatologica, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences and Community Health, University of Milan, Italy.
⁴ Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of Salerno, Baronissi, Italy; FIBROSYS s.r.l., Academic spin-off, University of Salerno, Baronissi, Italy. Electronic address: mcturco@unisa.it.
⁵ FIBROSYS s.r.l., Academic spin-off, University of Salerno, Baronissi, Italy; Scleroderma Clinic, UOC Clinica Reumatologica, ASST Pini-CTO, Milano, Italy. Electronic address: nicoletta.delpapa@asst-pini.cto.it.

No abstract available

Publication types